Articles From: Bill Barrett Corporation Schedules Year-End 2014 Financial and Operating Results Release and Conference Call to Bio-Techne Launches Simple Plex Platform


2014/12/8
Bill Carew, managing principal of Digital Benefit Advisor’s (DBA) ( digitalbenefitadvisors.com ) Hartford, Conn.
Sign-up for Bill Carew Named Senior Vice President of Growth for Digital Benefit Advisors investment picks
2015/1/13
By Wallace Witkowski, MarketWatch Gross tells Bloomberg he still has something to prove SAN FRANCISCO (MarketWatch) -- Bond guru Bill Gross admitted he was "blindsided" when Pimco, the firm he helped start, fired him last year.
Sign-up for Bill Gross says he was 'blindsided' by Pimco firing investment picks
2015/2/9
By Kirsten Grind Bill Gross in January took in his lowest amount from investors since he took the helm of a new mutual fund at Janus Capital Group Inc. about four monthsago, according to new data Monday from fund research firm Morningstar Inc. Mr.
Sign-up for Bill Gross Takes in Lowest Amount From Investors Since Taking Over Janus Fund investment picks
2014/12/15
The Federal Reserve might hold back from hiking interest rates in 2015 because of a lack of inflation, said bond guru Bill Gross in a CNBC interview on Monday.
Sign-up for Bill Gross: Disinflation may stop Fed from 2015 rate hike investment picks
2015/2/23
RenaissanceRe Holdings Ltd.
Sign-up for Bill Hagerty to Join RenaissanceRe Board of Directors investment picks
2015/2/11
HNRG Also Announces 3 Senior Management Team Appointments BOSTON , Feb.
Sign-up for Bill Peressini Named President Of Hancock Natural Resource Group investment picks
2014/12/5
ADVISORY, Dec.
Sign-up for BillerudKorsnas AB to Ring The Nasdaq Stock Market Closing Bell investment picks
2015/2/20
Billionaire investor Nelson Peltz has sold millions of Ingersoll-Rand stock (IR) for the second time in a week, according to a regulatory filing submitted on Friday by the industrial conglomerate.
Sign-up for Billionaire investor Peltz sells more Ingersoll-Rand stock investment picks
2015/1/21
Fiserv, Inc. (NASDAQ: FISV), a leading global provider of financial services technology solutions, today announced that Consolidated Edison of New York (Con Edison), the electric, gas and steam utility in New York City and Westchester County, New York, has implemented BillMatrix ® Payments from Fiserv.
Sign-up for BillMatrix Payments from Fiserv Enables Visa Card Payments for Con Edison Customers investment picks
2014/12/11
During its meeting held today the Board of Directors of Biloxi Marsh Lands Corporation (Pink Sheets: BLMC) declared a dividend of $.40 per outstanding share of common stock payable on Tuesday, December 30, 2014 to shareholders of record as of the close of business on Monday, December 22, 2014.
Sign-up for Biloxi Marsh Lands Corporation Declares Cash Dividend investment picks
2015/1/23
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that it has entered into an amendment of its existing credit facility from Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital (NYSE: HTCG). Under the amendment, the company borrowed an additional $15 million in growth capital, less the repayment of the outstanding balance on BIND’s existing term loan facility of approximately $3 million.
Sign-up for BIND Therapeutics Amends Credit Facility from Hercules Technology III, L.P. to Accelerate Accurin Pipeline Growth investment picks
2015/2/10
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the closing of its previously announced public offering of 3,739,130 units at the public offering price of $5.75 per unit.
Sign-up for BIND Therapeutics Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock investment picks
2015/2/4
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced that it is commencing an underwritten public offering of units consisting of shares of BIND’s common stock and warrants to purchase shares of BIND’s common stock.
Sign-up for BIND Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock investment picks
2015/1/22
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the publication of an article in the Journal of the American Medical Association ( JAMA ) co-authored by Robert S.
Sign-up for BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association investment picks
2015/2/5
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the pricing of its underwritten public offering of 3,739,130 units at the public offering price of $5.75 per unit.
Sign-up for BIND Therapeutics Prices Public Offering of Common Stock and Warrants to Purchase Common Stock investment picks
2015/1/7
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced its 2015 strategic overview and enrollment of the first patient expressing a KRAS mutation in a global, multicenter two-tiered phase 2 trial with BIND-014 in non-small cell lung cancer (NSCLC) patients with KRAS mutant tumors (mutated Kirsten ras oncogene homolog) or squamous histology.
Sign-up for BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview investment picks
2015/2/19
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that Andrew Hirsch, BIND’s chief operating officer and chief financial officer, will present at the Cowen & Co.
Sign-up for BIND Therapeutics to Present at Cowen & Co. 35th Annual Healthcare Conference investment picks
2014/11/30
Bing outlines the people, moments and events that shaped 2014 at http://www.BingTrends.com. REDMOND, Wash.
Sign-up for Bing shares the top searches of 2014 investment picks
2015/2/2
TEL AVIV, Israel, Feb.
Sign-up for Bio Blast Announces Key Leadership Changes investment picks
2014/12/2
TEL AVIV, Israel, Dec.
Sign-up for Bio Blast Pharma to Present Corporate Overview at the Oppenheimer & Co. 25th Annual Healthcare Conference investment picks
2015/2/10
TEL AVIV, Israel, Feb.
Sign-up for Bio Blast Pharma to Release Fourth Quarter and Fiscal Year 2014 Results on Tuesday, February 17 investment picks
2015/1/8
TEL AVIV, Israel, Jan.
Sign-up for Bio Blast Provides Update on Clinical Trial of Cabaletta(TM) for Occulopharyngeal Muscular Dystrophy (OPMD) investment picks
2015/2/9
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrollment into the safety segment of its Phase 2 study evaluating BP-100-1.01 (Liposomal Grb-2) in patients with acute myeloid leukemia (AML) .
Sign-up for Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients investment picks
2014/12/22
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma.
Sign-up for Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma investment picks
2015/1/6
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase™ 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30 p.m. Pacific Time.
Sign-up for Bio-Path Holdings to Present at the Biotech Showcase™ 2015 Conference investment picks
2015/1/7
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that data from pre-clinical studies of BP-100-1.01 (Liposomal Grb-2) were featured in the peer-reviewed journal Expert Opinion on Drug Delivery.
Sign-up for Bio-Path Holdings’ Liposomal Grb-2 Featured in Peer-Reviewed Journal “Expert Opinion on Drug Delivery” investment picks
2015/2/3
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1173114&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad to Report Fourth-Quarter and Full-Year 2014 Financial Results Thursday, February 26, 2015 investment picks
2015/2/3
MINNEAPOLIS , Feb.
Sign-up for Bio-Techne Declares Dividend investment picks
2015/1/22
MINNEAPOLIS , Jan.
Sign-up for Bio-Techne Launches Simple Plex Platform investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Bill Barrett Corporation Schedules Year-End 2014 Financial and Operating Results Release and Conference Call to Bio-Techne Launches Simple Plex Platform
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent